Track how companies discuss tariffs and trade policies in their earnings calls, and understand their impact across different industries and regions.
Although the tariff environment continues to be dynamic, we mobilized a cross-functional team and are actively managing and mitigating risks where possible.
As our customers navigate changes to US tariffs and trade policies, we're focused on helping them quickly adapt.
The current set of tariffs and exemptions represent about a 200 basis point hit to global gross margins in the first quarter.
If you are a bear on what's going to happen with the consumer, keep in mind, we have never had a prior downturn, a business segment that's growing like the digital segment is for us, if you look at where consensus is, where -- versus where we were last year, you would have to see a dramatic downturn in brick-and-mortar performance the last 8 months of the year for us to not be a significant grower of EBITDA this year.
The direct financial impact of existing tariff structures which are primarily between the U.S. and China is only $0.01 to $0.02 per quarter.
Based on the latest trade policy announcements, we expect minimal impact to fourth quarter financial performance due to tariffs.
We continue to monitor developments regarding pharmaceutical sector tariffs.
the implications for pricing power and the increased costs resulting from tariffs and how able individual companies and industries are to pass that on to end users.
We expect the annualized impact from tariffs and increased local supplier cost due to higher on-shoring demand to be a few hundred million dollars.
we've heard from a subset of advertisers that their spending has been impacted by the changes to the de minimis exemption